Cipla is currently trading at Rs. 875.25, up by 16.80 points or 1.95% from its previous closing of Rs. 859.85 on the BSE. The scrip opened at Rs. 865.95 and has touched a high and low of Rs. 881.05 and Rs. 862.65 respectively. So far 0.21 lakh shares were traded on the counter. The BSE … Read more
Cipla is planning to donate 5,000 nebulisers to primary health care centres in India as part of its initiative to improve access to nebulisation therapy specifically for patients in rural parts of the country. These nebulisers will be distributed at CHCs (community health centres) and PHCs (primary health centres) across several states. Maharashtra, Uttar Pradesh, … Read more
Cipla has been selected in the S&P Dow Jones Sustainability Index (DJSI) for the Emerging Markets for 2021. The DJSI family of indices is operated by one of the world’s leading index providers S&P Dow Jones. The Emerging Markets Index for the year comprises of 108 companies from 12 emerging economies, including China, Brazil, South … Read more
Cipla is currently trading at Rs. 800.10, up by 10.60 points or 1.34% from its previous closing of Rs. 789.50 on the BSE. The scrip opened at Rs. 795.00 and has touched a high and low of Rs. 801.40 and Rs. 790.55 respectively. So far 35726 shares were traded on the counter. The BSE group … Read more
Cipla is currently trading at Rs. 807.40, up by 1.85 points or 0.23% from its previous closing of Rs. 805.55 on the BSE. The scrip opened at Rs. 810.00 and has touched a high and low of Rs. 817.20 and Rs. 805.45 respectively. So far 151227 shares were traded on the counter. The BSE group … Read more
Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Valganciclovir Tablets 450mg from the United States Food and Drug Administration (USFDA). The company’s Valganciclovir Tablets 450mg is AB-rated generic therapeutic equivalent version of Roche’s Valcyte. It is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for use in the treatment … Read more
Cipla’s wholly owned subsidiary — Cipla Medpro South Africa (Pty) has completed the acquisition of 100% stake in Mirren (Pty) on October 22, 2018. Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range … Read more
